Till now, three immune checkpoint inhibitors have been approved by the FDA for the treatment of melanoma, including ipilimumab against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), as well as pembrolizumab and nivolumab against programmed cell death protein 1 (PD-1) [158]. Here, PDCD1 is linked to melanoma.